BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 27764820)

  • 1. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
    Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
    Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
    Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
    Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
    Isaacsson Velho PH; Castro G; Chung CH
    Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
    Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
    Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
    Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
    Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
    Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR
    Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
    Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
    Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
    Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
    Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
    Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells.
    Park SW; Hah JH; Oh SM; Jeong WJ; Sung MW
    BMC Cancer; 2016 Jul; 16():458. PubMed ID: 27411387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
    Tonlaar N; Galoforo S; Thibodeau BJ; Ahmed S; Wilson TG; Yumpo Cardenas P; Marples B; Wilson GD
    Radiother Oncol; 2017 Sep; 124(3):504-512. PubMed ID: 28823407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
    Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
    Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE; Jücker M
    Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
    Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
    Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma.
    Sun Y; Wang Z; Qiu S; Wang R
    Int J Biol Sci; 2021; 17(4):1104-1118. PubMed ID: 33867833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
    Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
    IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.